VISTAGEN THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Payments to Acquire Debt Securities, Available-for-sale of $5.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $5.60M, a 35.80% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $5.67M, a 44.93% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $5.87M, a 142.46% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $2.03M, a 84.62% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2026 was $22.30M, a 10.74% decline from fiscal 2025.
- VISTAGEN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $24.98M.
- VISTAGEN THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.60M 10-Q · filed 2026-08-14 | $11.27M derived: sum of 2 quarters · filed 2026-08-14 | $17.14M derived: sum of 3 quarters · filed 2026-08-14 | $19.18M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | $11.54M derived: sum of 2 quarters · filed 2026-06-15 | $13.58M derived: sum of 3 quarters · filed 2026-06-15 | $22.30M 10-K · filed 2026-06-15 |
| 2025-12-31 | $5.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $7.90M derived: sum of 2 quarters · filed 2026-02-12 | $16.63M 10-Q · filed 2026-02-12 | $20.54M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $2.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $10.76M 10-Q · filed 2025-11-13 | $14.67M derived: sum of 3 quarters · filed 2026-08-14 | $17.09M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $8.72M 10-Q · filed 2026-08-14 | $12.64M derived: sum of 2 quarters · filed 2026-08-14 | $15.06M derived: sum of 3 quarters · filed 2026-08-14 | $28.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | $6.34M derived: sum of 2 quarters · filed 2026-06-15 | $19.56M derived: sum of 3 quarters · filed 2026-06-15 | $24.98M 10-K · filed 2026-06-15 |
| 2024-12-31 | $2.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $15.64M derived: sum of 2 quarters · filed 2026-02-12 | $21.07M 10-Q · filed 2026-02-12 | $21.07M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $13.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $18.65M 10-Q · filed 2025-11-13 | $18.65M derived: sum of 3 quarters · filed 2025-11-13 | $18.65M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $5.42M 10-Q · filed 2025-08-07 | $5.42M derived: sum of 2 quarters · filed 2025-08-07 | $5.42M derived: sum of 3 quarters · filed 2025-08-07 | $5.42M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-17 | $0.00 derived: sum of 2 quarters · filed 2025-06-17 | $0.00 derived: sum of 3 quarters · filed 2025-06-17 | $0.00 10-K · filed 2025-06-17 |
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $0.00 derived: sum of 2 quarters · filed 2025-02-13 | $0.00 10-Q · filed 2025-02-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |